Cancer patients and coronavirus disease 2019: evidence in context
Open Access
- 15 August 2020
- journal article
- editorial
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 18 (1) , 1-3
Abstract
In the rapidly evolving coronavirus disease 2019 (COVID-19) outbreak, inherent literature has been increasing at an impressive rate. Such a dynamic scenario imposes the necessity to define a new framework for cancer care. The first emerging evidence has transmitted contrasting messages with regards to cancer care management. Some authors have hypothesized an increased infection risk for cancer patients, with a more severe disease, requiring a reorganization of health care system that could disrupt an established high quality cancer care routine in many developed countries. Other authors have attempted to interpret data related to cancer patients by better defining their “active status”. We herein present our point of view in the light of current evidence and based on the experience matured at our cancer institute in managing cancer patients during the COVID-19 pandemic. Our core idea is that “active cancer” may be considered a proxy of more recent exposure to diagnostic or therapeutic procedures, and the frequency of access to health care facilities can be predicted as a function of the severity of cancer symptoms. Hence, COVID-19 screening program and the adjustment of cancer care provision in a cancer institutions should be led by this risk model, while awaiting new evidence.Keywords
This publication has 11 references indexed in Scilit:
- Palliative Care for Patients With Cancer in the COVID-19 EraJAMA Oncology, 2020
- The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy RegionEuropean Journal of Cancer, 2020
- Excess mortality from COVID-19: a commentary on the Italian experienceInternational Journal of Public Health, 2020
- Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center HamburgOncology Research and Treatment, 2020
- Risk of COVID-19 for patients with cancerThe Lancet Oncology, 2020
- Controversies About COVID-19 and Anticancer Treatment with Immune Checkpoint InhibitorsImmunotherapy, 2020
- Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in ItalyJAMA, 2020
- COVID-19 and smoking: A systematic review of the evidenceTobacco Induced Diseases, 2020
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020
- Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancerEuropean Journal of Cancer, 2015